The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells

Biochemical and Biophysical Research Communications

Volumn 464, Issue 1, 2015, Pages 292-298

  Lu, Kang ^a   Chen, Na ^a   Zhou, Xiang Xiang ^a   Ge, Xue Ling ^a   Feng, Li Li ^a   Li, Pei Pei ^a   Li, Xin Yu ^a   Geng, Ling Yun ^a   Wang, Xin ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Histone deacetylase; Mantle cell lymphoma; Synergy

Indexed keywords

3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; BETA ACTIN; CYCLIN D1; HISTONE DEACETYLASE; STAT3 PROTEIN; VORINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; MESSENGER RNA; PYRIDINE DERIVATIVE; STAT3 PROTEIN, HUMAN; TYRPHOSTIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG POTENTIATION; DRUG RESISTANCE; FOLLICULAR LYMPHOMA; GENE CONTROL; HUMAN; HUMAN CELL; IN VITRO STUDY; MANTLE CELL LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MANTLE CELL LYMPHOMA; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, MANTLE-CELL; PYRIDINES; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TYRPHOSTINS;

EID: 84937637980     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.06.145     Document Type: Article

References (26)

1. P. Jares, D. Colomer, and E. Campo Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics Nat. Rev. Cancer 7 2007 750 762
2. S. Parekh, M.A. Weniger, and A. Wiestner New molecular targets in mantle cell lymphoma Semin. Cancer Biol. 21 2011 335 346
3. W. Weichert HDAC expression and clinical prognosis in human malignancies Cancer Lett. 280 2009 168 176
4. J. Tan, S. Cang, Y. Ma, R.L. Petrillo, and D. Liu Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents J. Hematol. Oncol. 3 2010 5
5. M. Ogura, K. Ando, T. Suzuki, K. Ishizawa, S.Y. Oh, K. Itoh, K. Yamamoto, W.Y. Au, H.F. Tien, Y. Matsuno, T. Terauchi, K. Yamamoto, M. Mori, Y. Tanaka, T. Shimamoto, K. Tobinai, and W.S. Kim A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma Br. J. Haematol. 165 2014 768 776
6. M. Kirschbaum, P. Frankel, L. Popplewell, J. Zain, M. Delioukina, V. Pullarkat, D. Matsuoka, B. Pulone, A.J. Rotter, I. Espinoza-Delgado, A. Nademanee, S.J. Forman, D. Gandara, and E. Newman Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma J. Clin. Oncol. 29 2011 1198 1203
7. A. Ferrajoli, S. Faderl, Q. Van, P. Koch, D. Harris, Z. Liu, I. Hazan-Halevy, Y. Wang, H.M. Kantarjian, W. Priebe, and Z. Estrov WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells Cancer Res. 67 2007 11291 11299
8. S. Verstovsek, T. Manshouri, A. Quintas-Cardama, D. Harris, J. Cortes, F.J. Giles, H. Kantarjian, W. Priebe, and Z. Estrov WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation Clin. Cancer Res. 14 2008 788 796
9. L.Y. Kong, M.K. Abou-Ghazal, J. Wei, A. Chakraborty, W. Sun, W. Qiao, G.N. Fuller, I. Fokt, E.A. Grimm, R.J. Schmittling, G.E. Archer Jr., J.H. Sampson, W. Priebe, and A.B. Heimberger A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells Clin. cancer Res. 14 2008 5759 5768
10. A. Iwamaru, S. Szymanski, E. Iwado, H. Aoki, T. Yokoyama, I. Fokt, K. Hess, C. Conrad, T. Madden, R. Sawaya, S. Kondo, W. Priebe, and Y. Kondo A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo Oncogene 26 2007 2435 2444
11. A. Horiguchi, T. Asano, K. Kuroda, A. Sato, J. Asakuma, K. Ito, M. Hayakawa, M. Sumitomo, and T. Asano STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma Br. J. Cancer 102 2010 1592 1599
12. K. Lu, X.S. Fang, L.L. Feng, Y.J. Jiang, X.X. Zhou, X. Liu, P.P. Li, N. Chen, M. Ding, N. Wang, J. Zhang, and X. Wang The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6 Cancer Lett. 359 2015 250 258
13. L. Zhang, J. Yang, J. Qian, H. Li, J.E. Romaguera, L.W. Kwak, M. Wang, and Q. Yi Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells Blood 120 2012 3783 3792
14. T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 70 2010 440 446
15. Y. Fujiwara, N. Yamamoto, Y. Yamada, K. Yamada, T. Otsuki, S. Kanazu, T. Iwasa, J.S. Hardwick, and T. Tamura Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors Cancer Sci. 100 2009 1728 1734
16. S.S. Ramalingam, S. Kummar, J. Sarantopoulos, S. Shibata, P. LoRusso, M. Yerk, J. Holleran, Y. Lin, J.H. Beumer, R.D. Harvey, S.P. Ivy, C.P. Belani, and M.J. Egorin Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study J. Clin. Oncol. 28 2010 4507 4512
17. O.A. O'Connor, M.L. Heaney, L. Schwartz, S. Richardson, R. Willim, B. MacGregor-Cortelli, T. Curly, C. Moskowitz, C. Portlock, S. Horwitz, A.D. Zelenetz, S. Frankel, V. Richon, P. Marks, and W.K. Kelly Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies J. Clin. Oncol. 24 2006 166 173
18. T. Watanabe, H. Kato, Y. Kobayashi, S. Yamasaki, Y. Morita-Hoshi, H. Yokoyama, Y. Morishima, J.L. Ricker, T. Otsuki, A. Miyagi-Maesima, Y. Matsuno, and K. Tobinai Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma Cancer Sci. 101 2010 196 200
19. A. Nishimoto, N. Kugimiya, T. Hosoyama, T. Enoki, T.S. Li, and K. Hamano JAB1 regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cells Biochem. Biophys. Res. Commun. 438 2013 513 518
20. R. Lai, G.Z. Rassidakis, L.J. Medeiros, V. Leventaki, M. Keating, and T.J. McDonnell Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours J. Pathol. 199 2003 84 89
21. L.V. Pham, A.T. Tamayo, C. Li, W. Bornmann, W. Priebe, and R.J. Ford Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications Mol. Cancer Ther. 9 2010 2026 2036
22. V.R. Fantin, A. Loboda, C.P. Paweletz, R.C. Hendrickson, J.W. Pierce, J.A. Roth, L. Li, F. Gooden, S. Korenchuk, X.S. Hou, E.A. Harrington, S. Randolph, J.F. Reilly, C.M. Ware, M.E. Kadin, S.R. Frankel, and V.M. Richon Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma Cancer Res. 68 2008 3785 3794
23. M. Gupta, J.J. Han, M. Stenson, L. Wellik, and T.E. Witzig Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy Leukemia 26 2012 1356 1364
24. C. Touzeau, C. Dousset, L. Bodet, P. Gomez-Bougie, S. Bonnaud, A. Moreau, P. Moreau, C. Pellat-Deceunynk, M. Amiot, and S. Le Gouill ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents Clin. Cancer Res. 17 2011 5973 5981
25. M. Furqan, A. Akinleye, N. Mukhi, V. Mittal, Y. Chen, and D. Liu STAT inhibitors for cancer therapy J. Hematol. Oncol. 6 2013 90
26. M. Ocker, and R. Schneider-Stock Histone deacetylase inhibitors: signalling towards p21cip1/waf1 Int. J. Biochem. Cell Biol. 39 2007 1367 1374